Viewing Study NCT05502250


Ignite Creation Date: 2025-12-24 @ 5:19 PM
Ignite Modification Date: 2026-02-20 @ 4:49 PM
Study NCT ID: NCT05502250
Status: RECRUITING
Last Update Posted: 2024-08-19
First Post: 2022-05-25
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission
Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module